EFFECT OF FOOD ON THE STEADY-STATE PHARMACOKINETICS OF RILPIVIRINE WHEN ADMINISTERED AS A FIXED-DOSE COMBINATION IN HIV-1 INFECTED UGANDAN ADULTS

Infectious Diseases Institute, Makerer University College of Health Sciences0 个研究点目标入组 15 人开始时间: 2013年1月7日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•1.Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study.
•2.Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
•3.Aged between 18 to 65 years, inclusive.
•4.Diagnosed with HIV-1 infection
•5.Receiving first-line ART containing tenofovir disoproxil fumarate, efavirenz plus either emtricitabine or lamivudine for a minimum of 6 months

•1.HIV-1 RNA > 400 copies/mL at screening visit
•2.Serum hemoglobin < 8g/dl
•3.Elevations in serum levels of alanine transaminase (ALT), aspartate transaminase (AST) or creatinine above 3 times the upper limit of normal
•4.Evidence of QT prolongation on electrocardiogram (ECG) QTc (Rate adjusted QT interval) >450ms (men) or >470ms (women)
•5.History of cardiac disease
•6.Diarrhea lasting greater than one week
•7.Use of known inhibitors or inducers of CYP3A4 .
•8.Use of antacids, histamine-2 blockers or proton pump inhibitors
•9.Use of herbal medications (information will be obtained from patients¿ medication history through interview with the patient)
•10.Consumption of grapefruit within 1 week of first dose of study drug and for the duration of the study
•11.Pregnant or lactating females
•12.Participation in other clinical studies within four weeks before the current study begins and/or during study participation. Subjects should not be concurrently enrolled in another clinical trial.

发起方

Infectious Diseases Institute, Makerer University College of Health Sciences